Cargando…

Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial

BACKGROUND: Fatigue is a common symptom in people with multiple sclerosis (pwMS) that significantly impairs quality of life. Bright light therapy may be a cheap treatment option with little to no adverse events. OBJECTIVES: To evaluate the effectiveness of bright light therapy as a treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voggenberger, Lisa, Böck, Marion, Moser, Doris, Lorbeer, Gudrun, Altmann, Patrick, Leutmezer, Fritz, Berger, Thomas, Seidel, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647309/ https://www.ncbi.nlm.nih.gov/pubmed/36387033 http://dx.doi.org/10.1177/20552173221133262

Ejemplares similares

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021)

Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial
por: Altmann, Patrick, et al.
Publicado: (2022)

Has the pandemic changed treatment strategy in multiple sclerosis?
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial
por: Altmann, Patrick, et al.
Publicado: (2022)

The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
por: Altmann, Patrick, et al.
Publicado: (2021)

Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort
por: Schurz, Natascha, et al.
Publicado: (2021)

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
por: Monschein, Tobias, et al.
Publicado: (2020)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

No Association of Multiple Sclerosis with C9orf72 Hexanucleotide Repeat Size in an Austrian Cohort
por: König, Theresa, et al.
Publicado: (2023)

Impact of vaccination on COVID‐19 outcome in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Exome-Sequence Analyses of Four Multi-Incident Multiple Sclerosis Families
por: Zrzavy, Tobias, et al.
Publicado: (2020)

Peripheral bright streaks in tuberous sclerosis
por: Eliesersdóttir, Torgerð Hentze, et al.
Publicado: (2021)

Serum neurofilament light chain withstands delayed freezing and repeated thawing
por: Altmann, Patrick, et al.
Publicado: (2020)

Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
por: Guger, Michael, et al.
Publicado: (2020)

New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
por: Zielińska-Nowak, Ewa, et al.
Publicado: (2020)

Fatigue Profiles in Patients with Multiple Sclerosis are Based on Severity of Fatigue and not on Dimensions of Fatigue
por: Beckerman, Heleen, et al.
Publicado: (2020)

Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2021)

COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome
por: Altmann, Patrick, et al.
Publicado: (2020)

Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2022)

Shams
Publicado: (1866)

Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options – Review Article
por: Zimek, Dalibor, et al.
Publicado: (2023)

Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short Version
por: Altmann, Patrick, et al.
Publicado: (2022)

Circadian Phase-Shifting Effects of Bright Light, Exercise, and Bright Light + Exercise
por: Youngstedt, Shawn D., et al.
Publicado: (2016)

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
por: Guger, Michael, et al.
Publicado: (2021)

Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0gjn9rf8307imup2a2qgvk57b3